Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 13/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478012 | 0.92 | PTK2 (0.51) | PTK2MAPTAXL | |
| SCHEMBL14644047 | 0.90 | CCND3 (0.51) | PTK2CCNA2CDK2CDK9CCNK | |
| SCHEMBL15524261 | 0.90 | CCNA2 (0.45) | PTK2CCNA2CDK2CDK9CCNK | |
| SCHEMBL14576576 | 0.88 | PTK2 (0.51) | PTK2FLT4 | |
| SCHEMBL15524518 | 0.86 | PTK2 (0.45) | PTK2FLT4 | |
| SCHEMBL14643607 | 0.85 | PTK2 (0.68) | PTK2FLT4 | |
| SCHEMBL14576814 | 0.85 | PTK2 (0.48) | PTK2FLT4 | |
| SCHEMBL14643595 | 0.84 | PTK2 (0.50) | PTK2FLT4 | |
| SCHEMBL15588222 | 0.84 | PTK2 (0.43) | PTK2ALKFLT4 | |
| SCHEMBL15524212 | 0.84 | FLT4 (0.50) | PTK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885CCNA2 268/4885CDK2 11/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885CCNA2 351/4885CDK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.